8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2009 (March 3, 2009)

SENSIVIDA MEDICAL TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

New Jersey	000-07405	22-1937826
(State or other jurisdiction	(Commission	(IRS Employer Identification No.)
of incorporation)	File Number)
77 Ridgeland Road Henrietta, New York		14623
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (585) 413-9080

N.A.

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.01 Completion of Acquisition or Disposition of Assets.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 2, 2009 Mr. Kamal Sarbadhikari resigned for health reasons as President of the registrant and a member of its Board of Directors effective December 31, 2009.  Jose Mir, now CTO of the registrant and a member of its Board of Directors, is appointed as the registrant’s interim President effective December 31, 2009.

Item 9.01 Exhibits and Financial Statements.

(d) Exhibits

17.1 Letter of resignation from Kamal Sarbadhikari dated November 2, 2009

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 6, 2009	SensiVida Medical Technologies, Inc.
	By:	/s/ Kamal Sarbadhikari
		Kamal Sarbadhikari
		Chief Executive Officer

3

EX-17.1

Exhibit 17.1

4

Date: November 2, 2009

To: David R. Smith, Chairman of the Board

From: Kamal Sarbadhikari

Subject: Resignation

Dear David,

Due to personal and health reasons, I am resigning as the President, CEO of SensiVida Medical Technologies. Given my health concerns, the all-consuming time pressures and the round-the-clock attendance to the duties of my position, it is not possible for me to continue. In the interest of my health and welfare – and for the sake of the shareholders – it is best that I resign. Please accept my resignation effective December 31, 2009. I am not planning to take any other job, nor starting any other company – I plan to retire to attend to personal matters.

In the interim, I will do my best to work through an orderly transition and identify any open issues and help resolve them. I pledge to help in defining a roadmap for the successor and work with the Board designated successor to make SensiVida a success story. Beyond December 31, 2009, circumstances permitting, I am willing to help the company and provide advice and counsel on specific matters as the need arises.

In closing, I wish SensiVida all the best in the future. We have great technology, great people and, I believe, we have made enormous progress to date. I want to thank you and the rest of the team for working so hard to achieve so much.

I wish nothing but the best for SensiVida in the future.

Sincerely,

/s/ Kamal Sarbadhikari

Kamal Sarbadhikari